TICKERNERD
Menu
FTREFTREHealthcare · Biotechnology

FTRE Stock Forecast: Fortrea Holdings, Inc. Price Predictions for 2026-2027

Last close, 15 Oct 2026
$23
+6.58% on the day

The 13 Wall Street analysts covering Fortrea Holdings, Inc. hold a median 12-month price target of $22 — -3.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 14 Oct 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$2.0B
Ticker Nerd rank
98 / 100
Median analyst target
$22
Analysts covering
13
Revenue$678.2M−4.5% y/y
Operating income$17.5M
Net income−$13.2M
Free cash flow$19.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+11.7%
1M
+15.3%
YTD
+31.9%
1Y
+134.7%
From 52W high
0.0%
From 52W low
+156.4%
$9
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FTRE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Fortrea Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
98 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
96
Accruals
95
Growth
93
Value
83
Revisions
83
Issuance
77
Quality
59
Size
35
Volatility
27

Momentum (96): The shares have been drifting up relative to others.

Volatility (27): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FTRE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FTRE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25Jan 26Apr 26Jul 26Oct 26FTREHigh $26Median $22Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
6 Buy5 Hold2 Sell
Low $14Median $22High $26

The green dot is the last close — the median target sits −3.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
6 Oct 2026BarclaysUpgradeOverweight$22 → $23
30 Sept 2026UBSInitiatesNeutral$22
4 Aug 2026TD CowenMaintainsBuy—
4 Aug 2026TD CowenMaintainsBuy$19 → $23
31 July 2026CitigroupMaintainsBuy—
31 July 2026CitigroupMaintainsBuy$20 → $22
30 July 2026BarclaysMaintainsEqual-Weight$18 → $22
30 July 2026BarclaysMaintainsEqual-Weight—
30 July 2026Evercore ISI GroupMaintainsOutperform$20 → $25
30 July 2026Evercore ISI GroupMaintainsOutperform—
30 July 2026Truist SecuritiesMaintainsBuy$19 → $26
30 July 2026Truist SecuritiesMaintainsBuy—
13 July 2026MizuhoMaintainsNeutral$13 → $16
13 July 2026MizuhoMaintainsNeutral—
24 June 2026BarclaysMaintainsEqual-Weight—
12 May 2026MizuhoMaintainsNeutral—
6 May 2026BarclaysMaintainsEqual-Weight—
6 May 2026CitigroupMaintainsBuy—
14 Apr 2026BarclaysMaintainsEqual-Weight—
8 Apr 2026Evercore ISI GroupMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FTRE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

FTRE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 15 Oct 2026, Fortrea Holdings, Inc. returned +134.7% against +16.9% for the S&P 500, dividends included.

FTRE vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26FTRES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FTRE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+4.7%
Analysts raising
7
Analysts cutting
4
Fundamentals

Fortrea Holdings, Inc. (FTRE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
522.3×

Cheaper than 1% of US stocks

Price / sales
0.8×

Cheaper than 74% of US stocks

Price / book
3.9×

Cheaper than 24% of US stocks

EV / EBITDA
29.9×

Cheaper than 9% of US stocks

Growth & margins
Revenue growth (YoY)
−4.5%

Higher than 20% of US stocks

Earnings growth (YoY)
—
Gross margin
20.5%

Higher than 22% of US stocks

Operating margin
2.6%

Higher than 50% of US stocks

Net margin
−3.2%

Higher than 26% of US stocks

Returns & dividend
Return on equity
−15.3%

Higher than 33% of US stocks

Return on assets
0.6%

Higher than 47% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Fortrea Holdings, Inc. (FTRE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Fortrea Holdings, Inc. has a market value of $2.0B and an enterprise value of $2.9B.

  • Revenue in the twelve months to 30 June 2026: $2.7B. The latest quarter shrank 4.5% year on year.

  • Net income over the same four quarters: −$85.2M, a −3.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.91.

  • Free cash flow in the twelve months to 30 June 2026: $196.0M, after $31.8M of capital spending.

  • Shares outstanding: 95.1M.

  • Trailing P/E: 522.3×; forward P/E: 18.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Fortrea Holdings, Inc. employs 14,000 people — $191K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

FTRE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FTREFortrea Holdings, Inc.$2.0B
98
IMNMImmunome, Inc.$2.0B
33
VRDNViridian Therapeutics, Inc.$2.0B
52
VCELVericel Corp.$2.0B
95
PHVSPharvaris NV$2.1B
40
IRONDisc Medicine, Inc.$2.1B
35
NVAXNovavax, Inc.$2.1B
61

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Fortrea Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FTRE news & analysis

3 Top Small-Cap Stocks With Market-Beating Momentum

Seeking Alpha · 15 Oct 2026neutral

Seeking Alpha highlights three fundamentally strong small-cap stocks that have outperformed the market since the Russell 2000’s recent high, despite broader small-cap weakness. It notes strategists see potential for a rebound if Treasury yields decline.

Why it matters — The article concerns small-cap market performance, providing context for investors tracking Fortrea, but the excerpt does not identify FTRE as one of the highlighted stocks.

Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call

GlobeNewsWire · 5 Oct 2026neutral

Fortrea announced it will release its third quarter 2026 financial results before the market opens on Thursday, October 29, 2026, and will host a conference call at 8:00 a.m. ET that day to discuss the results.

Why it matters — This informs Fortrea watchers of the scheduled date and time for the company's upcoming earnings report and related conference call.

Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 10 Sept 2026neutral

Fortrea announced on September 10, 2026, that it granted inducement awards of restricted stock units and performance share units to five newly hired employees. The awards were made under Nasdaq Listing Rule 5635(c)(4).

Why it matters — The grants indicate Fortrea is adding talent and using equity incentives to attract new hires.

Fortrea to Participate in September Investor Conferences

GlobeNewsWire · 10 Sept 2026neutral

Fortrea (Nasdaq: FTRE) announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations Tracy Krumme will participate in investor conferences in September, as announced on Sept. 10, 2026.

Why it matters — FTRE watchers tracking investor relations activity would note that the company's senior leadership is set to present at upcoming conferences.

Fortrea Leverages Early Phase Strengths to Accelerate Market Expansion

Benzinga · 2 Sept 2026positive

Fortrea has signed a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials in an all-cash transaction valued at approximately $45 million.

Why it matters — The acquisition leverages Fortrea's early phase strengths to accelerate its market expansion, which FTRE watchers would find relevant to the company's growth strategy.

FAQ

Frequently asked questions about FTRE stock

What is the FTRE stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Fortrea Holdings, Inc. have a median 12-month price target of $22, with estimates ranging from $14 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FTRE stock a buy right now?

Of the 13 analysts covering Fortrea Holdings, Inc., 6 rate it a Buy, 5 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Fortrea Holdings, Inc. 98 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FTRE?

As at 14 Oct 2026, Fortrea Holdings, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).

Will FTRE stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies -3.3% from the last close, and Ticker Nerd's factor model ranks Fortrea Holdings, Inc. 98 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FTRE stock forecast for 2030?

No analyst covering Fortrea Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FTRE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $26 over the next 12 months.

How has FTRE stock performed over the past year?

Fortrea Holdings, Inc. returned +134.7% over the 12 months to 15 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Fortrea Holdings, Inc. do?

Fortrea Holdings Inc. is a global contract research organization that provides clinical development solutions to pharmaceutical, biotechnology, and medical device companies.

What is the latest news on FTRE?

The most recent item we track (Seeking Alpha, 15 Oct 2026): "3 Top Small-Cap Stocks With Market-Beating Momentum". Seeking Alpha highlights three fundamentally strong small-cap stocks that have outperformed the market since the Russell 2000’s recent high, despite broader small-cap weakness. It notes strategists see potential for a rebound if Treasury yields decline.

Company

About Fortrea Holdings, Inc.

Fortrea Holdings Inc. is a global contract research organization that provides clinical development solutions to pharmaceutical, biotechnology, and medical device companies. Fortrea Holdings Inc. supports clients across the full clinical trial lifecycle, including Phase I through Phase IV studies, clinical pharmacology, data management, biostatistics, regulatory support, and post-approval evidence services. The company offers flexible delivery models such as full-service, functional service provider, and hybrid arrangements to fit different development needs. Its services are used by biopharma and medtech customers seeking to manage complex trials, improve operational efficiency, and generate the clinical evidence needed to advance products through development and approval. Fortrea Holdings Inc. is headquartered in Durham, North Carolina, and operates as a specialized services provider in the life sciences market.

CEO Mr. Anshul Thakral · 14,000 employees · United States · https://www.fortrea.com